Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies
The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases
Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer
SAN FRANCISCO, CA / ACCESS Newswire / June 9, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap on the company's assessment of the in-person Type C Meeting on May 28, 2025 with the Division of Gastroenterology of the U.S. Food and Drug Administration (FDA) to discuss the statistically significant responder analysis results for adult patients with breast cancer in Napo's recently conducted Phase 3 OnTarget trial.
"We were very happy to take part in the face-to-face Type C Meeting, the catalyst for which was the positive data in the subpopulation of breast cancer patients from our OnTarget trial," said Lisa Conte, Jaguar's founder, president, and CEO. "Napo proposed two simultaneous potential pathways during the meeting for making crofelemer available to metastatic breast cancer patients with the significant unmet medical need of CTD: conducting a pivotal treatment trial to facilitate approval of crofelemer for CTD in this focused patient population; and the prompt pursuit of authorization to initiate an expanded access program for breast cancer patients with CTD who may not be eligible for this study, including breast cancer patients in the adjuvant and neoadjuvant settings. We are pleased with the constructive and productive discussion that took place with the FDA during the meeting. Last week the FDA formally acknowledged both of these key discussion points in correspondence to Napo. We plan to submit a protocol to the FDA for a pivotal treatment trial for a smaller number of metastatic breast cancer patients using crofelemer."
Patient advocates participated in the Type C Meeting to share their raw and personal experience with CTD, including a metastatic breast cancer patient with uncontrollable diarrhea who received a prescription for crofelemer.
"The design of the protocol for OnTarget was based on a survey of cancer patients. Today there are close to 100 approved targeted cancer agents. Thanks to these amazing drugs, metastatic cancer patients are living longer, frequently rendering cancer, and CTD, chronic ailments with which to live. To deepen our understanding of the current population of metastatic cancer breast with CTD, and ensure the clinical meaningfulness of the design of the anticipated pivotal treatment trial, we plan to conduct a new survey of this cancer patient population," Conte said.
The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with the company's core focus on orphan diseases. The company therefore intends to request orphan drug designation from the FDA for the CTD indication in this population. Given crofelemer's novel and paradigm-shifting mechanism of action, the company also plans to seek Breakthrough Therapy designation and/or Fast Track designation from the FDA to support potentially expedited regulatory approval in the US for crofelemer for CTD in metastatic breast cancer patients.
"Embracing a sharp strategic focus on orphan indications seems to fit with the new administration's efforts and philosophy," said Conte. "Dr. Marty Makary, the new Commissioner of the FDA, commented in April 2025 that the agency will open a new regulatory pathway based on what he called a 'plausible mechanism,' focusing mainly on rare or incurable diseases."
As expressed during the Type C Meeting, the data from the first-of-its-kind prophylactic OnTarget study is invaluable, providing new insights into the natural history of the important and debilitating side effect of CTD. Diarrhea is a common side effect of targeted cancer therapies and can lead to dose changes, treatment delays, and often cessation of lifesaving cancer therapy. The benefit to risk ratio of crofelemer is well-documented, as the active agent has been commercialized for the approved indication of HIV-related diarrhea since 2012, with no crofelemer-related reported serious adverse events.
In both the US and European Union, crofelemer has been granted orphan drug designation for the orphan diseases of short bowel syndrome with intestinal failure and microvillus inclusion disease. Crofelemer has been granted orphan drug designation for treatment of diarrhea in cholera in the US, where cholera is an orphan disease. Orphan drug designation in the US qualifies the sponsor of a drug for various development incentives, including tax credits for qualified clinical testing and relief of filing fees. Additionally, orphan drug designation in the US provides a seven-year period of marketing exclusivity to the first sponsor who obtains marketing approval for the designated orphan drug.
While the multicenter, double-blind, placebo-controlled OnTarget pivotal trial did not meet its primary endpoint, the subgroup of adult breast cancer patients achieved statistically significant results in the responder analysis. In the responder analysis of patients with breast cancer on targeted therapies, crofelemer CTD prophylaxis resulted in a greater proportion of monthly responders of diarrhea improvement compared to placebo. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial of crofelemer for diarrhea in adults with 10 solid tumor types receiving targeted therapy with or without standard chemotherapy.
The OnTarget results in breast cancer patients were the subject of a poster presentation on December 11, 2024, at the San Antonio Breast Cancer Symposium, and additional significant results in adult breast cancer patients from the OnTarget study have been accepted for presentation as an oral rapid e-poster at the Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting in June 2025 in Seattle, Washington.
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the currently estimated US metastatic breast cancer population qualifies as an orphan population, Jaguar's expectation that the company will submit a protocol to the FDA for a pivotal treatment trial for a smaller number of metastatic breast cancer patients using crofelemer, Jaguar's expectation that it will promptly pursue authorization to initiate an expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer patients, and that the expanded access program would potentially include breast cancer patients in the adjuvant and neoadjuvant settings, Jaguar's expectation that Napo will conduct a clinical trial of crofelemer for treatment of CTD in patients with metastatic breast cancer, Jaguar's plans to seek Breakthrough Therapy designation and/or Fast Track designation from the FDA to support potentially expedited regulatory approval in the US for crofelemer for CTD in metastatic breast cancer patients, and Jaguar's expectation that additional significant results in adult breast cancer patients from the OnTarget study will be presented at the 2025 MASCC Annual Meeting. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
COVID Crusader Writes Open Letter To RFK Jr On mRNA
A prominent group of health activists is threatening a political revolt against HHS Secretary Robert F. Kennedy Jr. over what they call a betrayal of their movement's central cause. In a blistering open letter dated June 4, COVID crusader Dr. Mary Talley Bowden and several allies from the MAHA (Make America Healthy Again) movement — a grassroots coalition of vaccine-critical and medical freedom activists — accused Kennedy and FDA Commissioner Dr. Marty Makary of watering down policies related to the controversial mRNA vaccine platform, especially in guidance affecting children and pregnant women. 'We did not fight for you to be in positions of leadership so that our clearly stated policy goals would suffer a 'bait and switch,'' Bowden wrote, warning Kennedy that MAHA voters 'can walk away' if their demands are not met. The letter criticizes recent CDC and FDA policy changes, calling them deceptive and insufficient, and claims the administration is engaging in 'linguistic misdirections' to hide the continued recommendation of mRNA shots for vulnerable populations. The MAHA letter insists the mRNA platform — particularly COVID vaccines — should be pulled from the market entirely, citing adverse event data and peer-reviewed studies. It demands sweeping reforms: a full ban on mRNA technologies, repeal of the PREP Act, elimination of vaccine-related conflicts of interest in federal agencies, and an end to direct-to-consumer pharmaceutical advertising. The signatories include author Naomi Wolf, podcaster Shannon Joy, and several other activists who rose to prominence during the COVID-19 pandemic by challenging government vaccine narratives. The backlash comes amid growing scrutiny of RFK Jr.'s recent actions as HHS secretary. Once one the nation's most vocal mRNA vaccine skeptic, Kennedy has walked a careful line in office, telling Congress in May that his personal views on vaccines are 'irrelevant' and vowing not to make sudden changes to CDC policy. 'I don't think people should be taking medical advice from me,' Kennedy told lawmakers, as reported by The Hill on June 2. Still, his critics on both sides see Kennedy's recent moves as consequential. Late last month, he released a 58-second video on X stating that COVID vaccines for healthy children and healthy pregnant women had been removed from the CDC's immunization schedule — a declaration Bowden and others say was misleading. Indeed, as The Hill previously reported, the CDC quietly changed its guidance to say healthy children may receive the COVID vaccine after consultation with a healthcare provider, while maintaining stronger recommendations for other vulnerable categories. For pregnant women, the recommendation was similarly softened but not eliminated, and pregnancy remains classified by the FDA as a high-risk health condition, allowing continued vaccine use under certain circumstances. Bowden's letter zeroes in on this ambiguity, arguing that wordplay is being used to sustain vaccine availability under the appearance of reform. 'Pregnant women have not been made any safer by your wordplay,' she writes, warning that MAHA activists are prepared to run their own candidates in upcoming elections if their demands are ignored. The political threat underscores the friction between Kennedy and the movement that once celebrated his nomination. While Kennedy has taken steps to reshape HHS in ways consistent with his skepticism — including canceling hundreds of millions of dollars in funding for Moderna's mRNA flu vaccine— his first few months of actions have not thus far rendered the swift action that some would have hoped. Former CDC acting director Dr. Richard Besser and other public health experts have voiced alarm at Kennedy's willingness to circumvent the CDC's vaccine advisory panel, which has traditionally guided immunization policy through public, evidence-based deliberation. 'We're seeing a total side-stepping of the nation's leading public health agency,' Besser told The Hill. The vaccine panel has not yet weighed in on the updated COVID shot guidance. Its next meeting is scheduled for late June, and observers expect tense debate over whether Kennedy's changes represent science-based reform or political overreach. In the meantime, Bowden's warning reflects the fragile coalition Kennedy is attempting to hold together. The MAHA movement — built in part from disaffected MAGA voters, vaccine skeptics, and parents concerned about government overreach — played a pivotal role in rallying support for Kennedy's confirmation and the broader medical freedom agenda. Now, its leaders are openly questioning whether Kennedy's tenure will deliver the systemic change they demand — or whether they were simply used to fuel a political ascent. 'MAHA is not the possession of Secretary Kennedy,' Bowden wrote. 'It is the voice of millions of desperate parents… and their activism will outlast any administration.' The Dallas Express reached out to HHS but did not immediately receive a response. Kennedy previously spoke to The Dallas Express about a lawsuit Bowden brought against the FDA for misleading the public about using ivermectin for the treatment of COVID-19 during his presidential campaign in 2024 and just after the FDA settled the case. 'All three of the principal health agencies [CDC, NIH, FDA] suffer from agency capture,' Kennedy said. 'I would say 50% of the FDA's budget is from pharmaceutical companies. NIH scientists are allowed to collect royalties on drugs that they regulate –– which is clearly a conflict of interest. CDC … has devolved into an agency that primarily promotes the mercantile interests of the pharmaceutical companies.' He told DX that the agencies are overly influenced by perverse incentives from the pharmaceutical industry and added, 'I will change those incentives and unravel the culture of corruption that now has turned these agencies against public health.'
Yahoo
3 hours ago
- Yahoo
1.7 Million Cartons of Eggs Recalled for Salmonella Contamination
On June 6, the United States Food & Drug Administration (FDA) announced that August Egg Company of Hilmar, CA, is recalling 1.7 million dozen cage-free and certified organic eggs. The brown eggs, which were distributed in at least nine states, have been linked to a salmonella outbreak. According to the Centers for Disease Control & Prevention (CDC), there have been 79 reported salmonella infections so far, with 21 of those people being Name: Various brands of cage-free and organic eggs Date of Recall: June 6, 2025 Plant Code Number: P-6562 or CA5330 Distribution: Arizona, California, Illinois, Indiana, Nebraska, New Mexico, Nevada, Washington, WyomingSalmonella can cause severe gastrointestinal symptoms, such as stomach cramps, diarrhea, and fever. The symptoms of salmonella can start anywhere from six hours after eating contaminated food to six days after exposure. The recalled eggs were distributed in California and Nevada from February 3, 2025 to May 15, 2025 with sell by dates of March 4, 2025 to June 4, 2025, The eggs were sold at grocers including Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less, and Ralphs. The eggs were also distributed in Walmart stores from February 3, 2025 to May 6, 2025 with sell-by dates from March 4, 2025 to June 19, 2025. Walmarts in California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois sold the recalled eggs. This recall affects numerous brands of eggs, including Simply Truth Organic, which is sold at Kroger stores, and Marketside, which is sold at Walmart. Check for a full list of brands affected by the recall. If you have one of the affected cartons of eggs in your fridge, do not eat them. Instead, the FDA recommends returning the eggs to your place of purchase for a refund. If you have questions about this recall, contact August Egg Company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. Read the original article on SIMPLYRECIPES
Health Line
3 hours ago
- Health Line
Is There an Azstarys Shortage?
Azstarys is a prescription drug used to treat ADHD. Some ADHD medications have recently been in short supply. Learn whether Azstarys is affected and how to check its availability. Azstarys is not currently listed in the Food and Drug Administration (FDA) drug shortages database. Here's what to know about why some ADHD medications may be hard to find and how to check for drug shortages. Is there a shortage of other ADHD drugs? In recent years, several ADHD medications have been in short supply. A few examples include Adderall, Concerta, Ritalin, and Vyvanse. It's not yet clear when these shortages will fully resolve. These shortages have affected both brand-name and generic versions of the drugs. As a result, some people have worked with their doctor to switch to a different medication or adjust their ADHD treatment plan. To check the current status of Aztarys and other ADHD medications, visit the FDA drug shortages website. How do ADHD drug shortages affect people? Shortages of ADHD medications can make it harder for people to stick with their treatment plan. This can cause ADHD symptoms to return or become more difficult to manage. A lack of consistent access to ADHD medication may also increase stress and affect mental health. Other possible effects of disrupted access to ADHD medication include: difficulty focusing or completing daily tasks increased impulsivity or emotional outbursts difficulty falling or staying asleep withdrawing from social, family, or work activities If you're having trouble filling a prescription for an ADHD medication, talk with your doctor or pharmacist. They may recommend alternatives or adjust your treatment plan based on what's available. What causes a drug shortage? Several factors can lead to a medication being in short supply. Common causes of ADHD drug shortages include: Increased demand: More people receiving diagnoses of ADHD have led to greater demand for medications. This can strain manufacturers and reduce availability at pharmacies. Regulatory limits: Stimulant medications used to treat ADHD, including Azstarys, are controlled substances. The Drug Enforcement Administration (DEA) sets yearly production limits for these medications. If demand rises suddenly, these limits may contribute to shortages. Supply chain issues: Shortages of raw materials, packaging supplies, or labor can delay the manufacturing and availability of ADHD drugs. When multiple ADHD medications are in short supply at the same time, it can be especially hard for pharmacies to keep any option in stock. Even when generic forms are available, they may be affected by the same issues as brand-name drugs. As a result, generics may be just as difficult to find during a shortage. How can I check whether Azstarys is available near me? Azstarys is not currently listed by the FDA as being in shortage. However, some people may still experience delays when trying to fill their prescription. Availability can vary depending on your pharmacy, location, and insurance plan. If you're having trouble finding Azstarys, start by talking with a pharmacist. If possible, visit the pharmacy in person. Some pharmacies may not share inventory details for ADHD medications over the phone. You can also check pharmacy websites or apps, which sometimes offer tools to look up availability online. Keep in mind that availability may change as new shipments arrive. You can also check with your insurance provider. If Azstarys isn't available through your plan's preferred pharmacy, your insurer may be able to help you locate another pharmacy. In some cases, you may want to reach out to the drug manufacturer for information about availability in your area. To learn more about contacting the manufacturer, visit the Azstarys website.
